Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients December 2, 2021December 2, 2021 by Alejandro
IGC FYE2022 Form 8-K Favorable Preliminary Clinical Trial Results December 2, 2021December 2, 2021 by Alejandro
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability September 8, 2021September 8, 2021 by Alejandro
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC July 22, 2021 by Alejandro
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients June 24, 2021June 24, 2021 by Alejandro
